AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
PALM SPRINGS, CALIF. -- Routine vaginal cytology as a surveillance test for endometrial cancer recurrence is costly, inefficient, and benefits less than 1% of patients, Dr. Robert E. Bristow and his associates reported in a poster session at the annual meeting of the Society of Gynecologic Oncologists.
"The rationale for intensive surveillance of endometrial cancer patients in clinical remission is based on the premise that early detection of an asymptomatic recurrence will translate into improved survival outcomes," the researchers, who are affiliated with the Kelly Gynecologic Oncology Service at Johns Hopkins Medical Institutions, Baltimore, wrote in their poster.
Although this premise is widely held, studies have not demonstrated a significant survival advantage for patients whose recurrences are detected during routine follow-up, compared with symptomatic patients presenting for interval evaluation, they noted.
The researchers reviewed the medical records of 377 endometrial cancer patients who were treated at the Kelly Gynecologic Oncology Service between July of 1997 and June of 2005.
They calculated the total number of Pap tests performed during surveillance or until the time of recurrence. ...